Portal de Periódicos da CAPES

A glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus

2012; Wiley; Volume: 77; Issue: 4 Linguagem: Inglês

10.1111/j.1365-2265.2012.04368.x

1365-2265

S. K. Thondam, Daniel J. Cuthbertson, B. S. Aditya, I. A. MacFarlane, John Wilding, Christina Daousi,

Pharmacology and Obesity Treatment

Clinical EndocrinologyVolume 77, Issue 4 p. 635-637 Letter to the Editor A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus S. K. Thondam, S. K. Thondam [email protected] Department of Obesity & Endocrinology, University of Liverpool, Aintree University Hospitals NHS Foundation Trust, Liverpool, UKSearch for more papers by this authorD. J. Cuthbertson, D. J. Cuthbertson Department of Obesity & Endocrinology, University of Liverpool, Aintree University Hospitals NHS Foundation Trust, Liverpool, UKSearch for more papers by this authorB. S. Aditya, B. S. Aditya Department of Obesity & Endocrinology, University of Liverpool, Aintree University Hospitals NHS Foundation Trust, Liverpool, UKSearch for more papers by this authorI. A. MacFarlane, I. A. MacFarlane Department of Obesity & Endocrinology, University of Liverpool, Aintree University Hospitals NHS Foundation Trust, Liverpool, UKSearch for more papers by this authorJ. P. Wilding, J. P. Wilding Department of Obesity & Endocrinology, University of Liverpool, Aintree University Hospitals NHS Foundation Trust, Liverpool, UKSearch for more papers by this authorC. Daousi, C. Daousi Department of Obesity & Endocrinology, University of Liverpool, Aintree University Hospitals NHS Foundation Trust, Liverpool, UKSearch for more papers by this author S. K. Thondam, S. K. Thondam [email protected].ac.uk Department of Obesity & Endocrinology, University of Liverpool, Aintree University Hospitals NHS Foundation Trust, Liverpool, UKSearch for more papers by this authorD. J. Cuthbertson, D. J. Cuthbertson Department of Obesity & Endocrinology, University of Liverpool, Aintree University Hospitals NHS Foundation Trust, Liverpool, UKSearch for more papers by this authorB. S. Aditya, B. S. Aditya Department of Obesity & Endocrinology, University of Liverpool, Aintree University Hospitals NHS Foundation Trust, Liverpool, UKSearch for more papers by this authorI. A. MacFarlane, I. A. MacFarlane Department of Obesity & Endocrinology, University of Liverpool, Aintree University Hospitals NHS Foundation Trust, Liverpool, UKSearch for more papers by this authorJ. P. Wilding, J. P. Wilding Department of Obesity & Endocrinology, University of Liverpool, Aintree University Hospitals NHS Foundation Trust, Liverpool, UKSearch for more papers by this authorC. Daousi, C. Daousi Department of Obesity & Endocrinology, University of Liverpool, Aintree University Hospitals NHS Foundation Trust, Liverpool, UKSearch for more papers by this author First published: 22 February 2012 https://doi.org/10.1111/j.1365-2265.2012.04368.xCitations: 21Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Daousi, C., Dunn, A.J., Foy, P.M. et al. (2005) Endocrine and neuroanatomic features associated with weight gain and obesity in adult patients with hypothalamic damage. American Journal of Medicine, 118, 45– 50. 2Daousi, C., MacFarlane, I.A., English, P.J. et al. (2005) Is there a role for ghrelin and peptide-YY in the pathogenesis of obesity in adults with acquired structural hypothalamic damage? Journal of Clinical Endocrinology and Metabolism, 90, 5025– 5030. 3Ratner, R.E., Maggs, D., Nielsen, L.L. et al. (2006) Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 8, 419– 428. 4Buse, J.B., Klonoff, D.C., Nielsen, L.L. et al. (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clinical Therapeutics, 29, 139– 153. 5Gutzwiller, J.P., Göke, B., Drewe, J. et al. (1999) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut, 44, 81– 86. 6Alvarez, E., Martínez, M.D., Roncero, I. et al. (2005) The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. Journal of Neurochemistry, 92, 798– 806. 7Pannacciulli, N., Le, D.S.N.T., Salbe, A.D. et al. (2007) Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. NeuroImage, 35, 511– 517. Citing Literature Volume77, Issue4October 2012Pages 635-637 ReferencesRelatedInformation